UBS Group AG - TALIS BIOMEDICAL CORP ownership

Quarter-by-quarter ownership
UBS Group AG ownership history of TALIS BIOMEDICAL CORP
ValueSharesWeighting
Q2 2023$12
-7.7%
260.0%0.00%
Q1 2023$13
-99.6%
26
-99.6%
0.00%
Q4 2022$3,0356,743
+25834.6%
0.00%
Q3 2022$026
+30.0%
0.00%
Q2 2022$0
-100.0%
20
-99.3%
0.00%
Q1 2022$4,000
-86.7%
2,745
-63.3%
0.00%
Q4 2021$30,000
+400.0%
7,479
+1282.4%
0.00%
Q2 2021$6,000
-85.4%
541
-83.2%
0.00%
Q1 2021$41,0003,2110.00%
Other shareholders
TALIS BIOMEDICAL CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Greenlight Capital 2,235,783$1,095,5340.06%
Baker Brothers Advisors 7,624,835$3,736,1690.02%
PRELUDE CAPITAL MANAGEMENT, LLC 223,934$109,7280.01%
ArrowMark Colorado Holdings LLC 478,862$234,6420.00%
WELLS FARGO & COMPANY/MN 167$820.00%
NORTHERN TRUST CORP 27,860$13,6520.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GEODE CAPITAL MANAGEMENT, LLC 144,416$70,7630.00%
STATE STREET CORP 49,536$24,2730.00%
MILLENNIUM MANAGEMENT LLC 163,663$800.00%
View complete list of TALIS BIOMEDICAL CORP shareholders